Evaluation of circulating calcitonin: Analytical aspects

Tumori

Volumn 89, Issue 5, 2003, Pages 566-568

  Martinetti, Antonia ^a   Seregni, Ettore ^a   Ferrari, Leonardo ^a   Pallotti, Federica ^a   Aliberti, Gianluca ^a   Coliva, Angela ^a   Fracassi, Silvia ^a   Bombardieri, Emilio ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Calcitonin; Immunoradiometric assays; Medullary thyroid carcinomas

Indexed keywords

CALCITONIN; TUMOR MARKER;

ANTIBODY SPECIFICITY; ARTICLE; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC KIT; EVALUATION; HUMAN; IMMUNORADIOMETRIC ASSAY; INTERMETHOD COMPARISON; MONITORING; RADIOIMMUNOASSAY; THYROID MEDULLARY CARCINOMA;

EID: 0345735590     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160308900525     Document Type: Article

References (11)

1. Wimalawansa SJ, Bailey F: Validation, role in perioperative assessment, and clinical applications of an immunoradiometric assay for human calcitonin. Peptides, 16: 307-312, 1995.
2. Bieglmayer C, Scheuba C, Niederle B, Flores J, Vierhapper H: Screening for medullary thyroid carcinoma: experience with different immunoassays for human calcitonin. Wien Klin Wochenschr, 114: 267-273, 2002.
3. Lips CJM, Höppener JWM, Thössen JHH: Medullary thyroid carcinoma: role of genetic testing and calcitonin measurement. Ann Clin Biochem, 38: 1668-1679, 2001.
4. Sizemore GW, Hunter H III: Immunochemical heterogeneity of calcitonin in plasma of patients with medullary thyroid carcinoma. J Clin Invest, 55: 1111-1118, 1975.
5. Ghillani PP, Motté P, Troalen F, Jullienne A, Gardet P, Le Chevalier T, Rougier P, Schlumberger M, Bhuon C, Bellet D: Identification and measurement of calcitonin precursor in serum of patients with malignant diseases. Cancer Res, 49: 6845-6851, 1989.
6. Englebach M, Görges R, Forst T, Pfüter A, Dawood R, Heerdt S, Kunt T, Bockisch A, Beyer J: Improved diagnostic methods in the follow-up of medullary thyroid carcinoma by highly specific calcitonin measurement. J Clin Endocrinol Metab, 85: 1980-1984, 2000.
7. d'Herbomez M, Leclerc L, Vantyghem MC, Fourrier F, Proye C, Wemeau JL: Clinical evaluation of a new sensitive calcitonin assay: study of specificity. Clin Chim Acta, 311: 149-155, 2001.
8. Dermody WC, Rosen MA, Ananthaswamy R, McCormick WM, Levy AG: Characterization of the major forms of human calcitonin in tissue and serum. J Clin Endocrinol Metab, 52: 1090-1098, 1981.
9. Tobler PH, Tschopp FA, Dambacher MA, Born W, Fischer JA: Identification and characterization of calcitonin forms in plasma and urine of normal subjects and medullary carcinoma patients. J Clin Endocrinol Metab, 57: 749-754, 1983.
10. Seregni E, Pallotti F, Mattavelli F, Ferrari L, Martinetti A, Aliberti G, Villano C, Castellani MR, Bombardieri E: Diagnostic procedures in the follow-up of patients affected by MEN type 2. Tumori, 89: 563-565, 2003.
11. Conlon JM, Grimelius L, Thim L: Structural characterization of a high-molecular-mass form of calcitonin [procalcitonin-(60-116)-peptide] and its corresponding N-terminal flanking peptide [procalcitonin-(1-57)-peptide] in a human medullary thyroid carcinoma. Biochem, 256: 245-250, 1988.